Avrupa Birliği - Fransızca - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents contre la dermatite, à l'exclusion des corticostéroïdes - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Avrupa Birliği - Fransızca - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatite atopique - d'autres préparations dermatologiques - staquis est indiqué pour le traitement de légère à modérée de la dermatite atopique chez les adultes et les patients pédiatriques à partir de 2 ans ≤ 40% de la surface corporelle (bsa) affectés.

Avrupa Birliği - Fransızca - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatite atopique - d'autres préparations dermatologiques - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Belçika - Fransızca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

stallergènes s.a. - allergènes dermatophagoides farinae 50 ir (comprimé 100 ir); allergènes dermatophagoides pteronyssinus 50 ir (comprimé 100 ir); allergènes dermatophagoides farinae 150 ir (comprimé 300 ir); allergènes dermatophagoides pteronyssinus 150 ir (comprimé 300 ir) - comprimé sublingual - 100 ir - 300 ir - allergènes dermatophagoides farinae 50 ir; allergènes dermatophagoides pteronyssinus 50 ir; allergènes dermatophagoides farinae 150 ir; allergènes dermatophagoides pteronyssinus 150 ir - house dust mites

Avrupa Birliği - Fransızca - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite atopique - d'autres préparations dermatologiques - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Avrupa Birliği - Fransızca - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatite atopique - d'autres préparations dermatologiques - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Fransa - Fransızca - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teofarma - tioconazole 1 g - crème - 1 g - pour 100 g > tioconazole 1 g - antifongique (classe des imidazolés) code atc : d01ac07 - classe pharmacothérapeutique – antifongique a usage topique (d : médicaments dermatologiques).traitement des mycoses cutanées, surinfectées ou non par des bactéries, dues à : dermatophytes pityriasis versicolor candida érythrasma.